Provention Bio Inc

NASDAQ:PRVB   3:59:52 PM EDT
3.90
+0.11 (+2.90%)
Products

Provention Bio Announces FDA Acceptance Of The Biologics License Application (BLA) Resubmission For Teplizumab For The Delay Of Clinical Type 1 Diabetes In At-Risk Individuals

Published: 03/21/2022 11:28 GMT
Provention Bio Inc (PRVB) - Provention Bio Announces FDA Acceptance of the Biologics License Application (bla) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-risk Individuals.
Provention Bio Announces FDA Acceptance of the Biologics License Application (bla) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-risk Individuals.
Provention Bio Inc - FDA Sets Goal Date of August 17, 2022.
Provention Bio - Resubmitted Bla for Teplizumab for Delay of Clinical Type 1 Diabetes in At-risk Individuals Considered Complete, Class 2 Response to July 2021 Action Letter by FDA.